Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Sotera Health Company provides sterilization, and lab testing and advisory services in the United States, Canada, Europe, and internationally. The company's sterilization services include gamma and electron beam irradiation, and EO processing; Nelson Labs comprise microbiological and analytical chemistry testing; and advisory services for medical device and biopharmaceutical industries. It serves medical devices; pharmaceuticals; food and agricultural products; and commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2017 and is headquartered in Broadview Heights, Ohio.

Sotera Health Company

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Q2 2026 NET REVENUES INCREASED 9.2% OR 8.0% ON A CONSTANT CURRENCY BASIS (1) COMPARED TO Q2 2025 Q2 2026 NET INCOME OF $54 MILLION OR $0.19 PER DILUTED SHARE, COMPARED TO NET INCOME OF $8 MILLION OR $0.03 PER DILUTED SHARE IN Q2 2025 Q2 2026 ADJUSTED EBITDA ( 1 ) INCREASED 10.0%, OR 8.7% ON A CONSTANT CURRENCY BASIS Q2 2026 ADJUSTED EPS (1) OF $0.26, AN INCREASE OF 30% PER DILUTED SHARE COMPANY RAISES BOTH FULL-YEAR 2026 NET REVENUES GROWTH OUT LOOK TO 5.25% - 6.75% AND ADJUSTED EBITDA GROWTH OUTLOOK TO 5.75% - 7.25%, ON A CONSTANT CURRENCY BASIS CLEVELAND, AUG. 06, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE- AND SIX- MONTHS ENDED JUNE 30, 2026. WE DELIVERED ANOTHER STRONG QUARTER, WITH HIGH-SINGLE-DIGIT GROWTH, REFLECTING FOCUSED EXECUTION ACROSS ALL THREE OF OUR BUSINESS UNITS, SAID CHIEF EXECUTIVE OFFICER ALTON SHADER.

SOTERA HEALTH DELIVERS STRONG SECOND-QUARTER AND FIRST-HALF 2026 RESULTS AND RAISES FY 2026 OUTLOOK

CLEVELAND, JULY 23, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED ITS PLANS TO RELEASE ITS FINANCIAL RESULTS FOR THE SECOND-QUARTER ENDED JUNE 30, 2026 BEFORE THE MARKET OPENS ON THURSDAY, AUGUST 6, 2026. FOLLOWING THE RELEASE, MANAGEMENT WILL HOST A CONFERENCE CALL AT 9:00 A.M.

SOTERA HEALTH ANNOUNCES SECOND-QUARTER 2026 EARNINGS RELEASE DATE

CLEVELAND, MAY 11, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY) TODAY ANNOUNCED THE LAUNCH OF A SECONDARY OFFERING (THE OFFERING) OF 31,838,253 SHARES OF ITS COMMON STOCK, PAR VALUE $0.01 PER SHARE. ALL 31,838,253 SHARES ARE BEING OFFERED FOR SALE BY CERTAIN AFFILIATES OF WARBURG PINCUS LLC (WARBURG PINCUS) AND GTCR LLC (GTCR) AS SELLING STOCKHOLDERS.

SOTERA HEALTH ANNOUNCES SECONDARY OFFERING OF COMMON STOCK

Q1 2026 NET REVENUES INCREASED 10.0%, OR 6.5% ON A CO NSTANT CURRENC Y BASIS, COMPARED TO Q1 2025 Q1 2026 NET INCOME OF $27 MILLION OR $0.09 PER DILUTED SHARE, COMPARED TO A NET LOSS OF $13 MILLION OR $0.05 PER DILUTED SHARE IN Q1 2025 Q1 2026 ADJUSTED EBITDA ( 1 ) INCREASED 10.5%, OR 6.9% ON A CONSTANT CURRENCY BASIS Q1 2026 ADJUSTED EPS (1) OF $0.18 , AN INCREASE OF 29% PER DILUTED SHARE COMPANY REAFFIRMS FULL-YEAR 2026 OUTLOOK OF 5.0% - 6.5% NET REVENUES GROWTH AND 5.5% - 7.0% ADJUSTED EBITDA GROWTH, BOTH ON A CONSTANT CURRENCY BASIS COMPANY ANNOUNCED PLANNED CEO TRANSITION IN A SEPARATE RELEASE TODAY CLEVELAND, MAY 05, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE THREE MONTHS ENDED MARCH 31, 2026. WE DELIVERED A STRONG START TO THE YEAR, WITH SOLID REVENUE AND ADJUSTED EBITDA GROWTH WHILE DRIVING MARGIN EXPANSION, SAID CHAIRMAN AND CHIEF EXECUTIVE OFFICER, MICHAEL B.

SOTERA HEALTH DELIVERS STRONG FIRST-QUARTER 2026 RESULTS AND REAFFIRMS 2026 OUTLOOK

ALTON SHADER, CEO OF VIANT MEDICAL, TO BECOME CEO AND JOIN THE BOARD OF DIRECTORS, EFFECTIVE MAY 26, 2026 CHAIRMAN AND CEO MICHAEL B. PETRAS, JR. WILL SERVE AS EXECUTIVE CHAIRMAN OF THE BOARD OF DIRECTORS CLEVELAND, MAY 05, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED THE APPOINTMENT OF ALTON SHADER TO THE ROLE OF CHIEF EXECUTIVE OFFICER (CEO) OF THE COMPANY, EFFECTIVE MAY 26, 2026, AS PART OF A PLANNED LEADERSHIP TRANSITION.

SOTERA HEALTH ANNOUNCES LEADERSHIP TRANSITION

CLEVELAND, APRIL 21, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED ITS PLANS TO RELEASE ITS FINANCIAL RESULTS FOR THE FIRST-QUARTER ENDED MARCH 31, 2026 BEFORE THE MARKET OPENS ON TUESDAY, MAY 5, 2026. FOLLOWING THE RELEASE, MANAGEMENT WILL HOST A CONFERENCE CALL AT 9:00 A.M.

SOTERA HEALTH ANNOUNCES FIRST-QUARTER 2026 EARNINGS RELEASE DATE

CLEVELAND, MARCH 16, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY OR SOTERA HEALTH), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, ANNOUNCED TODAY THAT IT HAS APPOINTED KENNETH D. KRAUSE AS A NEW INDEPENDENT DIRECTOR TO ITS BOARD OF DIRECTORS (THE BOARD).

SOTERA HEALTH APPOINTS KENNETH D. KRAUSE TO THE BOARD OF DIRECTORS

CLEVELAND, MARCH 04, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC) (THE COMPANY) TODAY ANNOUNCED THE LAUNCH OF A SECONDARY OFFERING (THE OFFERING) OF 25 MILLIONSHARES OF ITS COMMON STOCK, PAR VALUE $0.01 PER SHARE. ALL 25 MILLION SHARES ARE BEING OFFERED FOR SALE BY CERTAIN AFFILIATES OF WARBURG PINCUS LLC (WARBURG PINCUS) AND GTCR LLC (GTCR) AS SELLING STOCKHOLDERS.

2025 NET REVENUES INCREASED 5.7% TO $1.164 BILLION , COMPARED TO 2024, OR 5.2% ON A CONSTANT CURRENCY BASIS 2025 NET INCOME INCREASED TO $78 MILLION OR $0.27 PER DILUTED SHARE, COMPARED TO NET INCOME OF $44 MILLION, OR $0.16 PER DILUTED SHARE, IN 2024 2025 ADJUSTED EBITDA (1) INCREASED 8.2% TO $594 MILLION, COMPARED TO 2024, OR 7.8% ON A CONSTANT CURRENCY BASIS 2025 ADJUSTED EPS (1) OF $0.86, AN INCREASE OF $0.16 PER DILUTED SHARE, COMPARED TO 2024 FULL-YEAR 2026 OUTLOOK: NET REVENUES GROWTH OF 5.0% TO 6.5% AND ADJUSTED EBITDA GROWTH OF 5.5% TO 7.0%, ON A CONSTANT CURRENCY BASIS CLEVELAND, FEB. 24, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (SOTERA HEALTH OR THE COMPANY) (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FOURTH-QUARTER AND FULL-YEAR 2025 AND ITS INITIAL 2026 OUTLOOK. FOURTH-QUARTER 2025 NET REVENUES INCREASED 4.6% TO $303 MILLION, COMPARED TO $290 MILLION IN THE FOURTH-QUARTER 2024.

SOTERA HEALTH DELIVERS 20TH CONSECUTIVE YEAR OF REVENUE GROWTH AND PROVIDES 2026 OUTLOOK

CLEVELAND, FEB. 17, 2026 (GLOBE NEWSWIRE) -- SOTERA HEALTH COMPANY (NASDAQ: SHC), A LEADING GLOBAL PROVIDER OF MISSION-CRITICAL END-TO-END STERILIZATION SOLUTIONS, LAB TESTING AND ADVISORY SERVICES FOR THE HEALTHCARE INDUSTRY, TODAY ANNOUNCED ITS PLANS TO RELEASE ITS FINANCIAL RESULTS FOR THE FOURTH-QUARTER AND FULL-YEAR ENDED DECEMBER 31, 2025 BEFORE THE MARKET OPENS ON TUESDAY, FEBRUARY 24, 2026. FOLLOWING THE RELEASE, MANAGEMENT WILL HOLD A CONFERENCE CALL AT 9:00 A.M.

Sotera Health Company

SHC

Price

Financial Reports

No items found.

Press Releases

Sotera Health Company

SHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

SHC